Murphy Laura, Pinney Sean P
Mount Sinai Medical Center, New York, NY, USA.
Mt Sinai J Med. 2012 May-Jun;79(3):317-29. doi: 10.1002/msj.21311.
Since its first performance in 1967, cardiac transplantation has emerged from a medical curiosity to become the treatment of choice for advanced heart failure. Refinements in surgical technique, development of a standardized endomyocardial biopsy grading system, and the discovery of newer immunosuppressive medications have improved the outlook for today's heart-transplant recipients. For the most recent era, median survival has increased to 10 years and median survival conditional upon surviving the first transplant year is now >14 years. Quality of life is excellent. This article will concisely review the major clinical outcomes following transplantation including survival, quality of life, immunosuppression, and short- and long-term complications.
自1967年首次开展心脏移植以来,它已从一种医学上的新奇事物发展成为晚期心力衰竭的首选治疗方法。手术技术的改进、标准化心内膜心肌活检分级系统的开发以及新型免疫抑制药物的发现,改善了当今心脏移植受者的前景。在最近一个时期,中位生存期已延长至10年,而在度过移植后的第一年存活下来的情况下,中位生存期现在超过14年。生活质量极佳。本文将简要回顾移植后的主要临床结果,包括生存率、生活质量、免疫抑制以及短期和长期并发症。